http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Han Ahram,Min Sangil,Jo Eun-Ah,Lee Hajeong,Kim Yong Chul,Han Seung Seok,Kang Hee Gyung,Ahn Yo Han,Oh Inseong,Song Eun Young,Ha Jongwon 대한진단검사의학회 2024 Annals of Laboratory Medicine Vol.44 No.1
Background: Whether anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody levels post-third coronavirus disease (COVID-19) vaccination correlate with worse outcomes due to breakthrough infection is unclear. We evaluated the association between anti-SARS-CoV-2 antibody levels and symptomatic breakthrough infection or hospitalization during the Omicron surge in kidney transplant recipients. Methods: In total, 287 kidney transplant recipients expected to receive a third vaccination were enrolled between November 2021 and February 2022. The Abbott SARS-CoV-2 IgG II Quant test (Abbott, Chicago, IL, USA) was performed within three weeks before and four weeks after the third vaccination. The incidence of symptomatic breakthrough infection and hospitalization from two weeks to four months post-third vaccination was recorded. Results: After the third vaccination, the seropositive rate and median antibody titer of the 287 patients increased from 57.1% to 82.2% and from 71.7 (interquartile range [IQR] 7.2–402.8) to 1,612.1 (IQR 153.9–5,489.1) AU/mL, respectively. Sixty-four (22.3%) patients had symptomatic breakthrough infections, of whom 12 required hospitalization. Lower anti-receptor-binding domain (RBD) IgG levels (<400 AU/mL) post-third vaccination were a risk factor for symptomatic breakthrough infection (hazard ratio [HR]=3.46, P<0.001). Anti-RBD IgG levels <200 AU/mL were a critical risk factor for hospitalization (HR=36.4, P=0.007). Conclusions: Low anti-spike IgG levels after third vaccination in kidney transplant recipients were associated with symptomatic breakthrough infection and, particularly, with hospitalization during the Omicron surge. These data can be used to identify patients requiring additional protective measures, such as passive immunization using monoclonal antibodies.
Sulfuretin, a natural Src family kinases inhibitor for suppressing solar UV-induced skin aging
Han, Ahram,Lee, Jinhyuk,Lee, Myung-hee,Lee, Sung-Young,Shin, Eun Ju,Song, Young-Ran,Lee, Kwang Min,Lee, Ki Won,Lim, Tae-Gyu Elsevier 2019 Journal of Functional Foods Vol.52 No.-
<P><B>Abstract</B></P> <P>This study suggests sulfuretin as an ant-skin aging agent. Sulfuretin significantly reduces solar UV (sUV)-increased matrix metalloproteinase-1 (MMP-1) expression and c-Jun phosphorylation in human dermal fibroblasts as well as skin tissue. An examination of the underlying mechanisms showed that sUV-activated MAPK signaling pathways are blocked by sulfuretin. Interestingly, sulfuretin directly inhibits the kinase activity of selected Src family. Because the amino acid sequence of Hck kinase which used kinase array is 230–497, it was assumed that sulfuretin interacts with this conserved domain of Src family kinase. It was also found that sulfuretin directly binds to sulfuretin with the lowest binding energy of −8.9 kcal/mol and free energy of −10.07 kcal/mol. Additionally, Hck protein was precipitated with sulfuretin-conjugated Sepharose 4B beads in HDFs cell lysate. Overall, present findings indicated that sulfuretin plays the role of anti-skin aging agent by acting as a general Src family kinase inhibitor in human skin.</P> <P><B>Highlights</B></P> <P> <UL> <LI> The anti-wrinkle formation activity of sulfuretin was suggested. </LI> <LI> Sulfuretin acts as general Src family kinase inhibitor. </LI> <LI> The expected interaction was assumed using computer modeling. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
Ahram Han,Seung-Kee Min 대한혈관외과학회 2023 Vascular Specialist International Vol.39 No.3
Atypical variceal bleeding, which primarily stems from extrahepatic portal vein obstruction (EHPVO), is a severe complication of pancreatic hepatobiliary surgery. This review provides insights into this condition’s incidence, diagnosis, and management strategies. The treatment modalities for atypical variceal bleeding resulting from EHPVO range from endoscopic intervention to surgical procedures, including direct variceal ligation and shunt surgery. Here, we discuss the efficacy and potential limitations of each treatment approach. Additionally, we explored the utility and therapeutic advantages of the meso-Rex shunt, a particularly promising surgical technique for mitigating the hemodynamic and metabolic impacts of EHPVO.
Isolated Dissection of the Celiac Artery after Blunt Trauma: A Case Report and Review of Literature
( Ahram Han ),( Jihun Gwak ),( Gangkook Choi ),( Jae Jeong Park ),( Byungchul Yu ),( Gil Jae Lee ),( Jin Mo Kang ) 대한외상학회 2017 大韓外傷學會誌 Vol.30 No.4
Traumatic dissection of the celiac artery without aortic dissection is a rare event. Here we describe two cases of celiac artery dissection after blunt abdominal trauma managed conservatively without surgical or endovascular intervention.
Type B Aortic Dissection with Visceral Artery Involvement Following Blunt Trauma: A Case Report
( Ahram Han ),( Min A Lee ),( Youngeun Park ),( Jin Mo Kang ),( Jung Ho Kim ),( Jungnam Lee ) 대한외상학회 2017 大韓外傷學會誌 Vol.30 No.4
Aortic dissection caused by blunt trauma is a rare injury that can be complicated by malperfusion syndrome resulting from obstruction of branch vessels of the aorta. Here, we present a case of traumatic type B aortic dissection with right renal and small bowel ischemia, successfully managed by endovascular fenestration.
Oncovascular Surgery: Essential Roles of Vascular Surgeons in Cancer Surgery
Ahram Han,Sanghyun Ahn,Seung-Kee Min 대한혈관외과학회 2019 Vascular Specialist International Vol.35 No.2
For the modern practice of cancer surgery, the concept of oncovascular surgery (OVS), defined as cancer resection with concurrent ligation or reconstruction of a major vascular structure, can be very important. OVS for advanced cancers requires specialized procedures performed by a specialized multidisciplinary team. Roles of oncovascular surgeons are summarized as: a primary surgeon in vesselorigin tumors, a rescue surgeon treating complications during cancer surgery, and a consultant surgeon as a multidisciplinary team for cancer surgery. Vascular surgeons must show leadership in cancer surgery in cases of complex advanced diseases, such as angiosarcoma, leiomyosarcoma, intravenous leiomyomatosis, retroperitoneal soft tissue sarcoma, iatrogenic injury of the major vessels during cancer surgery, pancreatic cancer with vascular invasion, extremity soft tissue sarcoma, melanoma and others.
Ahram Yi,Jun Hyung Lee,Hyeon Gyeong Nam,Jungsun Han,Sung-Eun Cho,Sang Gon Lee,Eun Hee Lee 대한임상검사정도관리협회 2022 Journal of Laboratory Medicine And Quality Assuran Vol.44 No.4
We validated an ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method for quantifying levetiracetam (LEV) and lamotrigine (LAM) in serum specimens. We developed an UHPLCMS/ MS method using Triple Quad 4500MD (SCIEX, Singapore) with 10 μM LEV- 2H3 (LEV-internal standard [IS]) and 10 μM LAM 13C3, d3 (LAM-IS) as internal standards. The mass spectrometer detected the transitions from the precursor to product ions (mass-to-charge ratio [m/z] 171.0→126.0 for LEV, m/z 177.1→132.1 for LEV-IS, m/z 256.0→210.9 for LAM, and m/z 262.1→216.8 for LAM-IS, respectively). We used a Kinetex (2.6 μm C18 100Å, 100×3.0 mm; Phenomenex, USA) column on an ExionLC AD UHPLC. The UHPLC-MS/ MS method yielded a linear response from 0.60 to 340.13 μg/mL for LEV (R 2=0.9997) and from 0.17 to 99.98 μg/mL for LAM (R 2=0.9995). The lower limits of quantification using this method were 0.60 and 0.17 μg/mL for LEV and LAM, respectively. The recovery of LEV and LAM UHPLC-MS/MS method measurements were within ±6% of the targeted values. The intra-day and inter-day coefficients of variation were all acceptable with values of less than 7% in both cases. Carry-over was not observed in any of the results. Ion suppression or enhancement was not observed in the blank and six samples for both LEV and LAM test results. The UHPLC-MS/MS LEV and LAM assay showed adequate recovery, precision, and sensitivity, and an adequate AMR, and thus is suitable for routine clinical work.
Ahram Yi,Jun Hyung Lee,Gahyun Yoo,Hye Jin Lim,Euna Park,Jungsun Han,Geun Young Kim,Sung-Eun Cho,Sang Gon Lee,Eun Hee Lee 대한임상검사정도관리협회 2021 Journal of Laboratory Medicine And Quality Assuran Vol.43 No.3
We validated a gas chromatography-mass spectrometry (GC-MS) method for quantifying pristanic acid (PrA) and phytanic acid (PhA) in plasma specimens. We developed a GC-MS method based on the analysis of 20 μM 2H3-pristanic acid (PrA-IS) and 80 μM 2H3-phytanic acid (PhA-IS) as internal standards. The GC-MS was fitted with a 30 m×0.25 mm×0.25 μm HP-5MS (Agilent, USA) column. The mass spectrometer was operated through the transitions from the precursor to the product ions (m/z [mass-to-charge ratio] 355, 369, 358, and 372 for PrA, PhA, PrA-IS, and PhA-IS, respectively). The retention times of PrA, PhA, PrA-IS, and PhA-IS were 19.33, 20.39, 19.31, and 20.38 minutes in a 26.83-minute analysis, respectively. Linearity, recovery, precision, and carryover were evaluated to validate the method. The GC-MS method yielded a linear response from 0.032 to 9.951 μmol/L for PrA (R 2=0.9999) and from 0.127 to 39.432 μmol/L for PhA (R 2=0.9998). The limits of quantification by the methods were 0.032 μmol/L for PrA and 0.127 μmol/L for PhA. The recovery of PrA and PhA GC-MS method measurements were within ±10% when evaluated with external quality assessment materials. The within-batch and total coefficients of variation were all below 6% for both PrA and PhA test results. Twenty-interday imprecision (%) were all below 5% for both PrA and PhA test results. Carry-over was found to be 0.001% for PrA and –0.008% for PhA. The GC-MS PrA and PhA assay showed adequate recovery, precision, sensitivity, and linearity. Hence, it is suitable for routine clinical work.